Invivyd to Advance Long COVID Treatment Study Amid Regulatory Uncertainty

Event summary

  • Invivyd and the SPEAR Study Group plan to initiate a Phase 2 clinical trial in mid-2026 to evaluate VYD2311 for Long COVID and COVID vaccine injury.
  • The trial will assess safety, efficacy, and biological mechanisms using multiple antibody doses and placebo controls.
  • VYD2311 is an antibody with broad antiviral activity against SARS-CoV-2 variants, leveraging a backbone similar to Invivyd’s PEMGARDA.
  • The study aims to address the significant unmet need for effective Long COVID treatments, affecting millions of individuals.

The big picture

Invivyd's move to target Long COVID represents a strategic pivot beyond acute COVID-19 prevention, capitalizing on a large and underserved patient population. However, the lack of established treatment paradigms and the complex pathophysiology of Long COVID introduce significant development and regulatory risks. The partnership with the SPEAR Study Group underscores the need for specialized expertise in this emerging therapeutic area, but also highlights the potential for scientific disagreements and delays.

What we're watching

Regulatory Risk
The success of the trial hinges on continued FDA acceptance of novel therapeutic approaches for Long COVID, a condition with evolving diagnostic criteria and limited regulatory precedent.
Clinical Efficacy
Whether VYD2311 demonstrates meaningful clinical benefit in a placebo-controlled trial, given the heterogeneity of Long COVID presentations and the challenges in measuring functional improvement, remains a key uncertainty.
Variant Evolution
The ongoing evolution of SARS-CoV-2 variants could diminish VYD2311’s efficacy, requiring continuous monitoring and potential adaptation of the antibody to maintain its antiviral activity.

Related topics

Pharmaceuticals Regulatory Approval Drug Development Biotechnology Clinical Trial Public Health